Epileptic Syndromes clinical trials at University of California Health
3 in progress, 2 open to eligible people
An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEE
open to eligible people ages 1 month to 6 years
To assess the long-term safety and tolerability of XEN496 in pediatric subjects with KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE) who had participated in the primary study (XPF-009-301).
at UCSF
XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy
open to eligible people ages 1 month to 6 years
To investigate the potential antiseizure effects of adjunctive XEN496 (ezogabine) compared with placebo in children with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE).
at UCSF
A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy
Sorry, not currently recruiting here
The purpose of the study is to evaluate the efficacy of perampanel as measured by the 50 percent (%) responder rate during the maintenance period of the core study for seizure frequency in participants with pediatric epileptic syndrome (Cohort 1) and partial-onset seizures (POS) (Cohort 2).
at UCLA
Last updated: